ACCESS PHARMACEUTICALS, INC. (BULLETIN BOARD: ACCP) has entered into an agreement with a leading commercial manufacturer to produce itsFDA-approved MuGard for North American distribution. One or more U.S. market seeding studies could begin as early as Q4 2009, the companysays (see also Pharmaceuticals <!--abembed-->
In a comparison of cancer patients receiving standard oral mucositis care with those patients receiving MuGard , MuGard has been shown to significantly reduce the incidence and severity of the debilitating side effect of radiation treatment and chemotherapy
Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral careregimen if mucositis develops. The market for the treatment of oral mucositis, expanding to include all patients undergoing chemotherapy and radiotherapy, is estimated to be in excess of $5 billion worldwide.
$0.0 (09/22/09)
